Clinical Integration of Genomic Medicine

Abstract

Genomic medicine has advanced from research promise to clinical reality across multiple domains: pharmacogenomic testing to guide drug selection, germline testing for hereditary cancer and cardiovascular disease risk, tumour molecular profiling to guide targeted therapy, and rapid whole-genome sequencing for critically ill neonates with suspected genetic disorders. The translation from genomic test availability to clinical integration -- the point at which genomic results reliably reach the clinicians and patients who can act on them and translate to improved clinical outcomes -- has been uneven across these domains and across European healthcare systems. Understanding which integration models most reliably convert genomic capability into patient benefit is essential for efficient investment of limited genomic medicine infrastructure resources. We evaluated five genomic medicine integration frameworks applied to 82,486 patients at 24 European genomic medicine centres in Rome, Stockholm, Amsterdam, Barcelona, and Warsaw between 2017 and 2024, covering pharmacogenomics, hereditary cancer, tumour profiling, and rare disease diagnosis. Frameworks ranged from referral-based genetic consultation through fully integrated genomic medicine platforms embedded in routine care pathways with decision support, laboratory integration, and result return infrastructure. Performance was benchmarked using our Genomic Medicine Integration Score (GMIS), integrating result turnaround time, clinical actionability, outcome impact, patient access equity, and pharmacogenomic implementation completeness. The embedded integrated platform framework achieved the highest GMIS (0.918), reducing time from test order to clinically actionable result from 38 days to 8 days and improving genomic result uptake in subsequent clinical decisions from 42.4% to 86.2%. Rare disease diagnosis through rapid WGS showed the largest absolute benefit, with diagnostic odyssey reduction from 4.2 years to 3.8 weeks in critical neonatal cases